Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Velocity-Based Resistance Training Effects on Inflammation in Older Adults

4. Mai 2026 aktualisiert von: National Taipei University

Dose-Response Effects of Velocity-Based Resistance Training on Anti-Inflammatory Responses in Older Adults

This study aims to investigate the effects of resistance training (RT) with different training volumes on immune modulation and anti-inflammatory responses in older adults. Participants will be randomly assigned to one of three RT volume groups (low, medium, or high) or a non-exercise control group. Participants in the training groups will complete a 4-week RT program, followed by a 4-week detraining phase. The findings are expected to provide evidence for volume-specific RT prescriptions to support healthy aging.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

60

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

  • Taiwan
      • Taipei, Taiwan, 116
        • Rekrutierung
        • National Taiwan Normal University
        • Kontakt:
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • Aged 60-75 years or older
  • No regular resistance training habit (defined as ≥2 sessions per week) in the past year
  • No musculoskeletal injuries within the past six months

Exclusion Criteria:

  • Obesity (BMI > 30 kg/m²), diabetes, hypertension, cancer, heart, kidney, or liver disease, or any other condition that may influence study outcomes.
  • Regular use of anti-inflammatory medications (e.g., NSAIDs).
  • Smoking or alcohol abuse
  • Inability to safely perform the prescribed resistance exercise movements
  • Unable to fully comprehend the study information and instructions.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: low training volume resistance exercise
Participants assigned to the low-volume resistance training group will perform one set per exercise at a load corresponding to 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% from the first repetition. Rest intervals of 2-3 minutes will be provided between exercises.
Sonstiges: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Experimental: medium training volume resistance exercise
Participants assigned to the medium-volume resistance training group will perform three sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
Sonstiges: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Experimental: high training volume resistance exercise
Participants assigned to the high-volume resistance training group will perform five sets per exercise at 80% of 1RM. Each set will be terminated when movement velocity decreases by 30% relative to the first repetition. Rest intervals of 90 seconds will be provided between sets, and 2-3 minutes between exercises.
Sonstiges: Resistance exercise
The RT program will consist of 12 sessions over a 4-week period, with participants training three times per week and at least one rest day between sessions. All sessions will be supervised by research personnel to ensure proper technique and safety. Exercises will be performed using resistance machines and will include chest press, shoulder press, seated row, lat pulldown, and leg press.
Kein Eingriff: sedentary control
Participants in control trial stayed sedentary during the period.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Changes in IL-6 concentration
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Plasma IL-6 concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble IL-6 receptor concentration
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble IL-6 receptor concentrations will be measured and reported in ng/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in soluble gp130 concentration
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Soluble gp130 concentrations will be measured and reported in ng/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-10 concentration
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-10 concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-1RA concentration
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
IL-1RA concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in TNF-α concentration
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
TNF-α concentrations will be measured and reported in pg/mL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Borgs Ratings of Perceived Exertion (RPE)
Zeitfenster: 1-hour during each exercise intervention
Borgs RPE is a method of estimating exertion rating, based on a 1 to 10 rating scale (1 being the no exertion at all, 10 being maximal exertion).
1-hour during each exercise intervention
Handgrip strength
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Maximal handgrip strength will be assessed using a digital hand dynamometer and reported in kilograms.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Knee extension strength
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Maximal voluntary isometric and isokinetic concentric knee extension strength of the dominant leg will be assessed using an isokinetic dynamometer and reported in Newton-meters.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
30-second chair-stand test
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lower-body functional capacity will be assessed by the number of repetitions completed during a 30-second chair-stand test.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Single-leg balance test
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Balance performance will be assessed as the duration of single-leg stance and reported in seconds.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Timed up and go test
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Functional mobility will be assessed using the Timed Up and Go test, with performance quantified as the time (seconds) required to stand up from a seated position, walk 3 meters, turn, walk back, and sit down.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SHIP1 protein expression in peripheral blood mononuclear cells (PBMCs)
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular SHIP1 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in gp130 (CD130) protein expression in PBMCs
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular gp130 (CD130) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in STAT3 protein expression in PBMCs
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular STAT3 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in phosphorylated STAT3 protein expression in PBMCs
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular phosphorylated STAT3 (p-STAT3) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in IL-6 receptor alpha (CD126) protein expression in PBMCs
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular IL-6 receptor alpha (CD126) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in Beta-2 adrenergic receptor (β2-AR) protein expression in PBMCs
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular β2-adrenergic receptor (β2-AR) protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in SOCS3 protein expression in PBMCs
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Intracellular SOCS3 protein expression in PBMCs will be measured and reported in arbitrary units.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in white blood cell count
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Total white blood cell count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in lymphocyte count
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lymphocyte count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in neutrophil count
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Neutrophil count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Changes in monocyte count
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Monocyte count will be measured and reported in cells/μL.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Body fat percentage will be measured using a body composition analyzer and reported as a percentage.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Lean body mass
Zeitfenster: Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining
Total lean body mass will be measured using a body composition analyzer and reported in kilograms.
Baseline, post-intervention (4 weeks), and at 2 and 4 weeks during detraining

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

National Taipei University

Ermittler

  • Hauptermittler: Shun-Hsi Tsai, Ph.D., National Taipei University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. April 2026

Primärer Abschluss (Geschätzt)

1. März 2029

Studienabschluss (Geschätzt)

1. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

15. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

28. April 2026

Zuerst gepostet (Tatsächlich)

5. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

8. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. Mai 2026

Zuletzt verifiziert

1. April 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • ECKIRB1140803

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Entzündungsreaktion

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Liberia

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren